Fig. 2

Multivariate model on the impact of prasugrel/ticagrelor, DES and duration of DAPT on inhospital and 1-year-outcomes of STEMI-patients with advanced CKD. Outcome models calculated for cumulative ischemic events at 1-year (ST + AMI + TLR) (A), inhospital bleedings (B), bleedings after discharge (within 1 year after the index event) (C) and overall mortality at 1-year (D). Multivariate model adjusted for age, gender, diabetes mellitus, anterior STEMI, cardiogenic shock, multivessel disease, and peak CK; P/T indicates prasugrel or ticagrelor (compared to clopidogrel); DES indicates drug-eluting stents (compared to BMS); > 6 mo indicates recommended dual antiplatelet therapy (DAPT) for longer than 6 months